NHS England sets target to save £1bn on medicines by 2029

NHS England has set a target to realise £1bn in medicines savings by 2029, with manufacturers’ representatives warning that the UK must be “conducive to suppliers” to meet this goal.

The target was revealed in board papers published on 27 March 2025, which listed improving commercial arrangements as a “key measure for next year”.

Having realised “close to £500m in medicines savings” in 2023/2024, the papers said NHS England “has set an ambition to save the NHS £1bn by 2029”.

NHS England is also targeting further cost-saving opportunities in the supply chain of around £500m in 2025/2026 and up to around £1bn by 2030.

The cost-saving target has followed the publication of a report on 19 March 2025 by the Company Chemists’ Association (CCA), which found that the number of price concessions granted for generic medicines increased by over 740% from 2015 to 2024.

The CCA report concluded that the medicines pricing system was creating a “false economy” in driving medicines shortages.

In January 2025, NHS England told The Pharmaceutical Journal that switching from original biologic to biosimilar medicines could save the NHS £1bn over five years.

Mark Samuels, chief executive of the British Generic Manufacturers Association, told The Pharmaceutical Journal: “The UK has the lowest medicine prices in Europe thanks to its well-established generic and biosimilar sector, which is underpinned by competition.

“Four out of five NHS patient prescriptions come from off-patent medicines, saving the NHS billions of pounds every year. In the next five years, another 250 products will lose their patent exclusivity, giving the NHS further significant savings opportunities.

“But for this to be fully realised, the UK must be conducive to suppliers, which requires government support. We must also retain critical NHS England capabilities, such as the Medicines Value and Access function, to deliver these substantial savings.

“The UK competes with other countries for stock allocations of medicines, and international companies will make rational decisions on where they send their limited supplies. Successive administrations have largely ignored the generics sector despite its intrinsic importance to the nation’s health.”

The NHS board papers also listed “tech and digital investment” as an important measure, specifically through investing in the rollout of electronic patient record systems, increasing coverage of the NHS Federated Data Platform and development of the NHS app.

“The NHS has committed to improving annual productivity growth by 2% for 2025/2026, with plans to continue to drive improvements [on] clinical and operational activity, to reduce costs and to improve wider efficiency,” the board papers said.